Synthetic Biologics, Inc.

Xyrofin Oy

Zuchem, Inc.

Synthetic Biologies, Inc.

Valtion Teknillinen Tutkimuskeskus

Hydrios Biotechnology Oy

Ulla Airaksinen

Pertti Koski

Katja Valimaki

Heikki Ojamo

Mats Walfridsson

Johan Hallborn

Merja Elisa Penttila

Sirkka Keranen

Barbel Hahn-Hagerdal

Merja Penttil&auml;

B&auml;rbel Hahn-H&auml;gerdal

Sirkka Ker&auml;nen

Niklas Von Weymarn

Sirkka Keraenen

Katja VÄLIMÄKI

Merja Penttilae

Katja Vaelimaeki

Baerel Hahn-Haegerdal

The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

Modified beta-lactamases and methods and uses related thereto

High concentration of free cells of heterofermentative lactic acid bacteria (LAB) in a resting or slowly growing state are used to convert fructose into mannitol. Efficient volumetric mannitol productivities and mannitol yields from fructose are achieved in a process applying cell-recycle, continuous stirred tank reactor and/or circulation techniques with native LAB cells or with LAB cells with inactivated fructokinase gene(s). Mannitol is recovered in high yield and purity with the aid of evaporation and cooling crystallization.

Process for producing D-mannitol

This invention relates to recombinant-DNA-technology. Specifically this invention relates to new recombinant yeast strains transformed with xylose reductase and/or xylitol dehydrogenase enzyme genes. A yeast strain transformed with the xylose reductase gene is capable of reducing xylose to xylitol and consequently of producing xylitol in vivo. If both of these genes are transformed into a yeast strain, the resultant strain is capable of producing ethanol on xylose containing medium during fermentation. Further, the said new yeast strains are capable of expressing the said two enzymes. Xylose reductase produced by these strains can be used in an enzymatic process for the production of xylitol in vitro.

Production of ethanol from xylose

This invention relates to recombinant-DNA-technology. Specifically, this invention relates to new recombinant yeast strains transformed with xylose reductase and/or xylitol dehydrogenase enzyme genes. A yeast strain transformed with the xylose reductase gene is capable of reducing xylose to xylitol and consequently of producing xylitol in vivo. If both of these genes are transformed into a yeast strain, the resultant strain is capable of producing ethanol on xylose containing medium during fermentation. Further, the said new yeast strains are capable of expressing the said two enzymes. Xylose reductase produced by these strains can be used in an enzymatic process for the production of xylitol in vitro.

Xylose utilization by recombinant yeasts

Growing community of inventors

Vantaa, Finland

Ulla Airaksinen